Enliven Therapeutics
ELVN
ELVN
170 hedge funds and large institutions have $2.44B invested in Enliven Therapeutics in 2026 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 62 increasing their positions, 32 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
94% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 32
36% more funds holding
Funds holding: 125 → 170 (+45)
0.13% less ownership
Funds ownership: 105.13% → 105% (-0.13%)
Holders
170
Holding in Top 10
10
Calls
$48.3M
Puts
$16.1M
Top Buyers
| 1 | +$64.3M | |
| 2 | +$43M | |
| 3 | +$20.7M | |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$20.4M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$18.3M |
Top Sellers
| 1 | -$51.4M | |
| 2 | -$46M | |
| 3 | -$41.7M | |
| 4 |
VA
VR Adviser
New York
|
-$41.6M |
| 5 |
CC
Commodore Capital
New York
|
-$39.3M |
